BWA
IMNM icon

Basecamp Wealth Advisors’s Immunome IMNM Stock Holding History

Basecamp Wealth Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35
Closed -$765 – 1909
2026
Q1 		$765 Sell
35
-21
-38% -$467 ﹤0.01% 1621
2025
Q4 		$1.2K Buy
+56
New +$983 ﹤0.01% 1454

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Basecamp Wealth Advisors's IMNM Position: Q2 2026 in Review

Basecamp Wealth Advisors sold out of Immunome (IMNM) in Q2 2026, closing a stake of 35 shares — an estimated $765 sold.

Basecamp Wealth Advisors first reported a position in IMNM in Q4 2025 and held it in 2 quarters. The position peaked at $1.2K in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Basecamp Wealth Advisors reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
  • Basecamp Wealth Advisors sold 35 Immunome shares in Q2 2026, an estimated $765.
  • Basecamp Wealth Advisors first reported a position in Immunome in Q4 2025 and held it in 2 quarters.
  • Basecamp Wealth Advisors's Immunome position peaked at $1.2K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.